APO-ERLOTINIB

Prezentare produs

About APO-ERLOTINIB

APO-ERLOTINIB is a prescription medication containing the active ingredient Erlotinib Hydrochloride, used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is a type of epidermal growth factor receptor (EGFR) inhibitor, which works by blocking the action of a protein that promotes the growth of cancer cells.

Key Benefits & Uses

• Treatment of non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations
• Treatment of pancreatic cancer in combination with gemcitabine in patients with locally advanced or metastatic disease
• May be used as a maintenance therapy to prevent cancer recurrence in patients with NSCLC who have responded to initial treatment

Active Ingredient & Action

Erlotinib Hydrochloride is a small molecule inhibitor that selectively targets the EGFR tyrosine kinase, preventing the activation of downstream signaling pathways that promote cell proliferation and survival. By blocking the EGFR pathway, Erlotinib Hydrochloride inhibits the growth and spread of cancer cells, ultimately leading to tumor shrinkage and improved patient outcomes.

Important Notes

APO-ERLOTINIB should only be used under the guidance of a qualified healthcare professional. Patients should be closely monitored for signs of adverse effects, including skin rash, diarrhea, and liver damage. Regular blood tests and liver function tests are recommended to ensure safe and effective treatment.